<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087786</url>
  </required_header>
  <id_info>
    <org_study_id>2016-NBTL-S-005</org_study_id>
    <nct_id>NCT03087786</nct_id>
  </id_info>
  <brief_title>Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations</brief_title>
  <official_title>Randomized, Parallel-Group, Assessor Blind Study To Evaluate Oral Mucosal Effects In Healthy Adult Smokers Associated With 3 Week Use Of Nicotine Bi-tartrate 4mg Mint Lozenges Relative To The Use Of Nicotine Polacrilex 4mg Mint Lozenges</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niconovum USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inflamax Research Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Niconovum USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the oral mucosal effects in adult smokers associated with the use of two Nicotine&#xD;
      Lozenge formulations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the oral mucosal health associated with 3 weeks of use of test product, Nicotine&#xD;
      Bitartrate 4 mg mint lozenge, relative to a reference product, Nicorette® [Nicotine&#xD;
      Polacrilex] 4 mg mint lozenge, in healthy adult smokers motivated to quit smoking.&#xD;
&#xD;
      To evaluate the safety and tolerability of Nicotine Bitartrate 4 mg mint lozenge and&#xD;
      Nicorette® [Nicotine Polacrilex] 4 mg mint lozenge in this subject population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Actual">August 13, 2017</completion_date>
  <primary_completion_date type="Actual">August 13, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OMI-20 Total Score Change From Baseline to Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OMI-20 Total Score Change From Baseline to Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OMI-20 Total Score Change From Baseline to Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OMI-20 Total Score Change From Baseline to Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Erythema Subscore Change From Baseline to Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Erythema Subscore Change From Baseline to Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Erythema Subscore Change From Baseline to Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Erythema Subscore Change From Baseline to Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Ulcer Subscore Change From Baseline to Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Ulcer Subscore Change From Baseline to Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Ulcer Subscore Change From Baseline to Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMI-20 Ulcer Subscore Change From Baseline to Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Day 21</time_frame>
    <description>Count of the number of participants with Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 21</time_frame>
    <description>Count of the number of participants with Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Due to Adverse Events (AEs)</measure>
    <time_frame>Day 21</time_frame>
    <description>Count of the number of participants who discontinued due to Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Nicotine Bitartrate 4mg Lozenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Polacrilex 4mg Lozenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Bitartrate Lozenge 4mg</intervention_name>
    <description>Test Product</description>
    <arm_group_label>Nicotine Bitartrate 4mg Lozenge</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Polacrilex 4Mg Lozenge</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Nicotine Polacrilex 4mg Lozenge</arm_group_label>
    <other_name>Nicorette Lozenge 4mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Potential subjects who meet the following criteria at Screening may be included in the&#xD;
        study.&#xD;
&#xD;
          1. Sex and Age: Males and females aged at least 18 years and older.&#xD;
&#xD;
          2. Informed of the nature of the study and have agreed to and are able to read, review,&#xD;
             and sign the informed consent document prior to commencing any study specific&#xD;
             procedures. The informed consent document will be written in English, therefore the&#xD;
             volunteer must have the ability to read and communicate in English.&#xD;
&#xD;
          3. Must have smoked at least 10 cigarettes per day for the previous 12 months prior to&#xD;
             screening.&#xD;
&#xD;
          4. Must smoke first cigarette within 30 minutes of waking up.&#xD;
&#xD;
          5. Must be motivated to quit smoking upon enrollment into the study.&#xD;
&#xD;
          6. Contraception: Females of childbearing potential who have been, in the opinion of the&#xD;
             Investigator, practicing a reliable method of contraception for at least two months&#xD;
             prior to study participation and must agree to remain on an acceptable method of&#xD;
             contraception while participating in the study period using the study medication.&#xD;
             Acceptable methods of contraception are hormonal birth control, intrauterine device,&#xD;
             double barrier methods, vasectomized partner or abstinence.&#xD;
&#xD;
          7. Females of childbearing potential will be required to undergo a serum (Screening) and&#xD;
             urine (Day 0) pregnancy test (must be negative).&#xD;
&#xD;
          8. Females of non-childbearing potential must be surgically sterile for at least three&#xD;
             months prior to Screening or post-menopausal for at least two years.&#xD;
&#xD;
          9. General health: All study participants must have good general health and no impairment&#xD;
             that would impede or affect ability to participate in the study as deemed acceptable&#xD;
             by the Investigator.&#xD;
&#xD;
         10. Compliance: All study participants must understand and be willing to comply with all&#xD;
             study procedures and restrictions.&#xD;
&#xD;
         11. Consent: All study participants must demonstrate willingness to participate as&#xD;
             evidenced by voluntary written informed consent and must have received a signed and&#xD;
             dated copy of the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
          2. Nicotine use:&#xD;
&#xD;
               1. Is unable/unwilling to stop using forms of tobacco (e.g., traditional cigarettes,&#xD;
                  chewing tobacco, nicotine gels, cigars, snuff tobacco, nicotine patch and&#xD;
                  electronic cigarettes) for the duration of the study.&#xD;
&#xD;
               2. Is unable/unwilling to stop using other nicotine replacement therapy products&#xD;
                  throughout the duration of the study.&#xD;
&#xD;
          3. Disease: Has a medical history, which in the opinion of the investigator, would&#xD;
             jeopardize the safety of the subject or impact the validity of the study results,&#xD;
             e.g., known history of heart disease, recent myocardial infarction or cerebrovascular&#xD;
             accident (i.e., within 12 weeks prior to enrollment), unstable angina, severe cardiac&#xD;
             arrhythmia, diabetes or peptic ulcer.&#xD;
&#xD;
          4. Demonstrates a reactive screen for Hepatitis B surface antigens, hepatitis C antibody,&#xD;
             or HIV antibody.&#xD;
&#xD;
          5. Oral condition:&#xD;
&#xD;
               1. Has history of oral surgery (including extractions) within four weeks of&#xD;
                  screening, operative dental work within seven days of screening, or a presence of&#xD;
                  any clinically significant oral pathology (as determined by an oral health&#xD;
                  professional - dentist or dental hygienist) including lesions, sores or&#xD;
                  inflammation of the mouth which would interfere with study assessments or&#xD;
                  confound the results.&#xD;
&#xD;
               2. Has fixed retainers, orthodontic appliances, or either maxillary and/or&#xD;
                  mandibular dentures or other appliances which may interfere with the placement of&#xD;
                  the product.&#xD;
&#xD;
               3. Has current or recurrent disease that could affect the site of application, the&#xD;
                  action, absorption of the study treatment, or clinical assessment.&#xD;
&#xD;
               4. Has severe gingivitis, periodontitis or rampant caries (extensive dental decay,&#xD;
                  i.e., big/deep cavities, in many teeth), as diagnosed by an oral health&#xD;
                  professional- dentist or dental hygienist.&#xD;
&#xD;
               5. Has the presence of oral or peri-oral ulceration including herpetic lesions at&#xD;
                  screening (subjects with these lesions may be re-examined at a subsequent&#xD;
                  appointment and may be able to be admitted at a later date if the ulceration or&#xD;
                  herpetic lesion heals) or Study Visit Day 0.&#xD;
&#xD;
               6. Has elective dentistry scheduled during the study duration.&#xD;
&#xD;
          6. Allergy/Intolerance:&#xD;
&#xD;
               1. Has a known or suspected intolerance or hypersensitivity to the study materials&#xD;
                  (or closely-related compounds) or any of their stated ingredients.&#xD;
&#xD;
               2. Has a known genetic deficiency with an inability to metabolize aspartame or&#xD;
                  phenylalanine or has been diagnosed with phenylketonuria.&#xD;
&#xD;
          7. Clinical Study Participation:&#xD;
&#xD;
               1. Participation in another clinical study or receipt of an investigational drug&#xD;
                  within 30 days of the screening visit at the start of the study.&#xD;
&#xD;
               2. Previous participation in this study.&#xD;
&#xD;
          8. Substance abuse:&#xD;
&#xD;
               1. Current or recent (within two years of screening) history of drug or alcohol&#xD;
                  abuse, misuse, physical or psychological dependence.&#xD;
&#xD;
               2. Demonstrates a positive alcohol breath test.&#xD;
&#xD;
               3. Demonstrates a positive urine drug screen without disclosure of corresponding&#xD;
                  prescribed concomitant medication(s) at Screening and Study Visit Day 0.&#xD;
&#xD;
          9. Urine glucose:&#xD;
&#xD;
             a) Positive glucose urine screen.&#xD;
&#xD;
         10. Personnel:&#xD;
&#xD;
               1. Is an employee of the Sponsor or the study site.&#xD;
&#xD;
               2. Is a member of the same household as another subject in this trial.&#xD;
&#xD;
         11. Use of all over the counter (OTC) and prescription (Rx) lozenges after starting the&#xD;
             study (Day 0 and onward).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Lee, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inflamax Research Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inflamax Research Inc</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <results_first_submitted>August 29, 2018</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03087786/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03087786/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Bitartrate 4mg Lozenge</title>
          <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Polacrilex 4mg Lozenge</title>
          <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject in the Nicotine Bitartrate group (Male, White, Age 21) was provided the study drug, but was then lost to followup. No evidence of ever taking any study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Bitartrate 4mg Lozenge</title>
          <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
        </group>
        <group group_id="B2">
          <title>Nicotine Polacrilex 4mg Lozenge</title>
          <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="13.53"/>
                    <measurement group_id="B2" value="39.0" spread="10.94"/>
                    <measurement group_id="B3" value="39.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Particiapnts with OMI-20 Score of 0.00</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.&#xD;
Only subjects without any oral pathology (as determined by an oral health professional - dentist or dental hygienist) including lesions, sores or inflammation of the mouth were included in the study (OMI-20 score of 0.00).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OMI-20 Total Score Change From Baseline to Day 3</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 3</time_frame>
        <population>MITT: Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Total Score Change From Baseline to Day 3</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
          <population>MITT: Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OMI-20 Total Score Change From Baseline to Day 7</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 7</time_frame>
        <population>MITT: Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Total Score Change From Baseline to Day 7</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
          <population>MITT: Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OMI-20 Total Score Change From Baseline to Day 14</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 14</time_frame>
        <population>MITT: Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Total Score Change From Baseline to Day 14</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
          <population>MITT: Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OMI-20 Total Score Change From Baseline to Day 21</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 21</time_frame>
        <population>MITT: Modified Intent to Treat (no change in any participant was observed in the Nicotine Bitartrate arm)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Total Score Change From Baseline to Day 21</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 consists of nine items measuring erythema, nine measuring ulceration, one measuring atrophy, and one measuring edema; all are scored from 0 [none] to 3 [severe] and summed for a total possible score of 0-60.&#xD;
A higher score means a worse outcome.</description>
          <population>MITT: Modified Intent to Treat (no change in any participant was observed in the Nicotine Bitartrate arm)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Erythema Subscore Change From Baseline to Day 3</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 3</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Erythema Subscore Change From Baseline to Day 3</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Erythema Subscore Change From Baseline to Day 7</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 7</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Erythema Subscore Change From Baseline to Day 7</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Erythema Subscore Change From Baseline to Day 14</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 14</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Erythema Subscore Change From Baseline to Day 14</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Erythema Subscore Change From Baseline to Day 21</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 21</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed in the Nicotine Bitartrate arm)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Erythema Subscore Change From Baseline to Day 21</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring erythema, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed in the Nicotine Bitartrate arm)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Ulcer Subscore Change From Baseline to Day 3</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 3</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Ulcer Subscore Change From Baseline to Day 3</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Ulcer Subscore Change From Baseline to Day 7</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 7</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Ulcer Subscore Change From Baseline to Day 7</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Ulcer Subscore Change From Baseline to Day 14</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 14</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Ulcer Subscore Change From Baseline to Day 14</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OMI-20 Ulcer Subscore Change From Baseline to Day 21</title>
        <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
        <time_frame>Day 21</time_frame>
        <population>Modified Intent to Treat (no change in any participant was observed in the Nicotine Bitartrate arm)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>OMI-20 Ulcer Subscore Change From Baseline to Day 21</title>
          <description>Scale Title: The 20 Item Oral Mucositis Index (OMI-20)&#xD;
The OMI-20 contains a subset of nine items measuring ulcers, all are scored from 0 [none] to 3 [severe], and summed for a total possible score of 0-27.&#xD;
A higher score means a worse outcome.</description>
          <population>Modified Intent to Treat (no change in any participant was observed in the Nicotine Bitartrate arm)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>Count of the number of participants with Adverse Events.</description>
        <time_frame>Day 21</time_frame>
        <population>Modified Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>Count of the number of participants with Adverse Events.</description>
          <population>Modified Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>Count of the number of participants with Serious Adverse Events</description>
        <time_frame>Day 21</time_frame>
        <population>Modified Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>Count of the number of participants with Serious Adverse Events</description>
          <population>Modified Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Due to Adverse Events (AEs)</title>
        <description>Count of the number of participants who discontinued due to Adverse Events.</description>
        <time_frame>Day 21</time_frame>
        <population>Modified Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Bitartrate 4mg Lozenge</title>
            <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Polacrilex 4mg Lozenge</title>
            <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to Adverse Events (AEs)</title>
          <description>Count of the number of participants who discontinued due to Adverse Events.</description>
          <population>Modified Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Bitartrate 4mg Lozenge</title>
          <description>Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Bitartrate Lozenge 4mg: Test Product</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Polacrilex 4mg Lozenge</title>
          <description>Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days&#xD;
Nicotine Polacrilex 4Mg Lozenge: Active Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dispepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhorea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor and the PI have a Confidentiality Agreement stating:&#xD;
Each Party shall not disclose Confidential Information publicly or to any third party in an unauthorized manner.&#xD;
Each Party's obligations of confidentiality, non-disclosure and limited use imposed by this Agreement shall not apply to information or items that are required to be disclosed by governmental authority or by judicial process.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Abraham Varghese</name_or_title>
      <organization>Niconovum USA</organization>
      <phone>336-741-2315</phone>
      <email>varghea@rjrt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

